Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exubera Lung Test Will Be Advised Until More Data Is Collected, FDA Says

Executive Summary

A recommendation for patients taking Pfizer's Exubera to get lung function tests every six to 12 months will continue until the agency has more information on the product's effect on the lungs from post-marketing studies

You may also be interested in...



MannKind’s Long, Winding Development Road Ends In Approval Of Afrezza Inhaled Insulin

Firm now faces the commercial gauntlet of establishing an inhaled insulin in the crowded diabetes market.

Ghosts of Exubera Haunt Afrezza As Lung Function, Cancer Concerns Weigh Heavily

FDA advisory committee review of MannKind’s inhaled insulin revisits safety issues that troubled Pfizer’s first-of-its-kind product, including a potential lung cancer risk and declines in pulmonary function.

Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead

Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta

Related Content

Latest News
UsernamePublicRestriction

Register

PS046803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel